All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22nd 2023

For patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-related adverse effect.

Zanidatamab Plus Chemo Displays Early Activity in HER2+ Metastatic Gastroesophageal Adenocarcinoma

February 22nd 2023

The combination of zanidatamab and standard chemotherapy demonstrated activity when used as a first-line treatment for patients with HER2-positive metastatic or advanced gastroesophageal adenocarcinoma.

New Options Poised to Make a Splash in Metastatic Prostate Cancer

February 21st 2023

Matthew Rettig, MD, discusses emerging treatment options for patients with stage IV metastatic prostate cancer and highlights key data from clinical trials in the space.

PSMA-PET Highlights Evolution of Molecular Imaging in Prostate Cancer

February 21st 2023

Andrei H. Iagaru, MD, discusses molecular imaging and the use of prostate-specific membrane antigen PET scans in prostate cancer and highlights other key presentations from the 2023 Prost8 Cancer Conference.

Combination Regimens May Expand PARP Inhibitor Efficacy in mCRPC

February 21st 2023

Tian Zhang, MD, MHS, discusses findings with single-agent PARP inhibitors within homologous recombination repair–deficient metastatic castration-resistant prostate cancer and describes how these advances pave the way for combining PARP inhibitors with hormonal therapies.

New Technology Advances Prostate Cancer Care But Questions Linger

February 21st 2023

Phillip J. Koo, MD, highlights insights garnered from prostate cancer experts on topics such as radioligands and modern radiopharmaceuticals, which, along with artificial intelligence, have the potential to revolutionize the field.

Toripalimab Plus Chemotherapy Meets PFS End Point in PD-L1+ TNBC

February 21st 2023

Toripalimab plus nab-paclitaxel demonstrated a significant improvement in progression-free survival compared with placebo and nab-paclitaxel in PD-L1–positive patients with stage IV or recurrent/metastatic triple-negative breast cancer.

Multidisciplinary Discussions Move the Needle Toward Innovative Prostate Cancer Care

February 21st 2023

Michael S. Cookson, MD, MMHC, explains how discrepancies in defining biochemical recurrence are sparking a conversation about creating more consistent definitions that could allow for more widely applicable standards of care in prostate cancer .

Nivolumab Plus Salvage Immunotherapy Leads to High TFS Rates in Advanced RCC

February 21st 2023

Nivolumab monotherapy, plus salvage nivolumab plus ipilimumab for progressive disease, resulted in high treatment-free survival rates in patients with previously untreated advanced clear cell renal cell carcinoma.

MHRA Approves Selinexor Plus Bortezomib/Dexamethasone for Multiple Myeloma Following 1 Prior Therapy

February 21st 2023

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted full marketing authorization for selinexor in combination with bortezomib and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior therapy.

Jaime Merchán, MD, Named Sylvester’s Translational and Clinical Oncology Research Program Co-Leader

February 21st 2023

Jaime Merchán, MD, is the new Translational and Clinical Oncology Research Program co-leader at Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System.

The Implications of the Underappreciated, Evolving View of Cancer as a Chronic Illness

February 21st 2023

Successful manipulation of the immune system to achieve regression of cancer, long an unfulfilled goal of oncologic investigation, is an ever-increasing reality in multiple clinical settings.

First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma

February 20th 2023

The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.

Avelumab Efficacy Holds-Up In A Real-World Analysis of Patients With Locally Advanced, Metastatic Urothelial Carcinoma

February 20th 2023

The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.

Sacituzumab Govitecan Represents Improved Later-line Option Vs Chemotherapy in Metastatic HR+/HER2– Breast Cancer

February 20th 2023

Tiffany A. Traina, MD, discusses the significance of the FDA approval of sacituzumab govitecan for patients with metastatic hormone receptor-positive, HER2-negative breast cancer and expanded on the data from TROPiCS-02 that supported the approval.

Clinical Activity With High-dose HPN217 Warrants Continued Research in R/R Multiple Myeloma

February 20th 2023

Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.

Florida Cancer Specialists & Research Institute Appoints Hitesh Patel, MD to Executive Board

February 20th 2023

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

Therapeutic Advances Rapidly Expand the Breast Cancer Armamentarium Across Subtypes

February 20th 2023

An increasing focus on antibody-drug conjugates for HER2-positive breast cancer signals a potential shift in the standard of care for this population.

Slow Burn to Wildfire: How Do We Douse the Flames of Burnout in Oncology?

February 20th 2023

Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.

Erdafitinib Data in FGFR+ Cholangiocarcinoma Indicates Utility of NGS in Treatment Selection

February 20th 2023

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.